Table 1 The basic characteristics of eligible patients in ATO and RIF groups.

From: Long-term outcome of children with acute promyelocytic leukemia: a randomized study of oral versus intravenous arsenic by SCCLG-APL group

 

Total

N = 176

ATO groups

N = 85

RIF groups

N = 91

p

Median age, years (range)

8.2 (1.0,15.9)

7.9 (1.0,14.6)

8.8 (1.5,16.6)

0.613

Male, n (%)

105 (59.7)

57 (67.1)

48 (52.7)

0.053

Median WBC, ×109/L (range)

4.5 (0.3,228.0)

4.4 (0.3,228.0)

4.8 (0.8,74.7)

0.876

Median PLT, ×109/L (range)

25.5 (4.0,226.0)

26.5 (4.0,135.0)

24.0 (4.0,226.0)

0.723

Median Hb, g/L (range)

74.5 (31.0,141.0)

74.0 (31.0,131.0)

76.0 (37.0,141.0)

0.321

Sanz risk, n (%),

 Low-risk

34 (19.3)

15 (17.6)

19 (20.9)

0.804

 Intermediate-risk

85 (48.3)

43 (50.6)

42 (46.2)

 High-risk

57 (32.4)

27 (31.8)

30 (32.9)

CNSL at diagnosis

0

0

0

  1. WBC white blood cell count, PLT platelet counts, Hb hemoglobin level, Low-risk APL WBC ≤ 10 × 109/L and PLT ≥ 40 × 109/L, intermediate-risk WBC ≤ 10×109/L and PLT < 40 × 109/L, high-risk WBC > 10 × 109/L at diagnosis, CNSL central nervous system leukemia defined as having clinical signs of facial nerve palsy, hypothalamic syndrome, etc., and/or MRI evidence of intracranial, intradural mass.
Back to article page